230 related articles for article (PubMed ID: 23042670)
21. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY
J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586
[TBL] [Abstract][Full Text] [Related]
22. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.
Valerio CJ; Schreiber BE; Handler CE; Denton CP; Coghlan JG
Arthritis Rheum; 2013 Apr; 65(4):1074-84. PubMed ID: 23280155
[TBL] [Abstract][Full Text] [Related]
23. Computer-Aided Tomographic Analysis of Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc). Correlation with Pulmonary Physiologic Tests and Patient-Centred Measures of Perceived Dyspnea and Functional Disability.
Salaffi F; Carotti M; Di Donato E; Di Carlo M; Ceccarelli L; Giuseppetti G
PLoS One; 2016; 11(3):e0149240. PubMed ID: 26930658
[TBL] [Abstract][Full Text] [Related]
24. The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease.
Wilsher M; Good N; Hopkins R; Young P; Milne D; Gibson A; Suppiah R; Ly J; Doughty R; Dalbeth N
Respirology; 2012 May; 17(4):647-52. PubMed ID: 22256786
[TBL] [Abstract][Full Text] [Related]
25. Effects of pulmonary rehabilitation on dyspnea, quality of life, and healthcare costs in California.
California Pulmonary Rehabilitation Collaborative Group
J Cardiopulm Rehabil; 2004; 24(1):52-62. PubMed ID: 14758104
[TBL] [Abstract][Full Text] [Related]
26. The effects of short-term and long-term pulmonary rehabilitation on functional capacity, perceived dyspnea, and quality of life.
Verrill D; Barton C; Beasley W; Lippard WM
Chest; 2005 Aug; 128(2):673-83. PubMed ID: 16100153
[TBL] [Abstract][Full Text] [Related]
27. The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma.
Sekhon S; Pope J; ; Baron M
J Rheumatol; 2010 Mar; 37(3):591-8. PubMed ID: 20080913
[TBL] [Abstract][Full Text] [Related]
28. Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study.
Hsu VM; Chung L; Hummers LK; Wigley F; Simms R; Bolster M; Silver R; Fischer A; Hinchcliff ME; Varga J; Goldberg AZ; Derk CT; Schiopu E; Khanna D; Shapiro LS; Domsic RT; Medsger T; Mayes MD; Furst D; Csuka ME; Molitor JA; Alkassab F; Steen VD
Semin Arthritis Rheum; 2014 Aug; 44(1):55-62. PubMed ID: 24709277
[TBL] [Abstract][Full Text] [Related]
29. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
30. Validation of a Dyspnea Visual Analog Scale in Fibrotic Interstitial Lung Disease.
Bevanda L; Mok V; Lin K; Assayag D; Fisher JH; Johannson KA; Khalil N; Kolb M; Manganas H; Marcoux V; Sadatsafavi M; Wong AW; Ryerson CJ
Ann Am Thorac Soc; 2024 Jul; 21(7):1007-1014. PubMed ID: 38315632
[No Abstract] [Full Text] [Related]
31. Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients.
Hager WD; Collins I; Tate JP; Azrin M; Foley R; Lakshminarayanan S; Rothfield NF
Clin Respir J; 2013 Jul; 7(3):227-36. PubMed ID: 22789029
[TBL] [Abstract][Full Text] [Related]
32. Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease.
Chen T; Tsai APY; Hur SA; Wong AW; Sadatsafavi M; Fisher JH; Johannson KA; Assayag D; Morisset J; Shapera S; Khalil N; Fell CD; Manganas H; Cox G; To T; Gershon AS; Hambly N; Halayko AJ; Wilcox PG; Kolb M; Ryerson CJ
Respir Res; 2021 Jul; 22(1):202. PubMed ID: 34238283
[TBL] [Abstract][Full Text] [Related]
33. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
34. Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis.
Baron M; Hudson M; Steele R; Lo E;
J Rheumatol; 2011 Sep; 38(9):1925-30. PubMed ID: 21724704
[TBL] [Abstract][Full Text] [Related]
35. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.
Williams MH; Handler CE; Akram R; Smith CJ; Das C; Smee J; Nair D; Denton CP; Black CM; Coghlan JG
Eur Heart J; 2006 Jun; 27(12):1485-94. PubMed ID: 16682379
[TBL] [Abstract][Full Text] [Related]
36. Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: results from the ACOSOG Z4032 (Alliance) multicenter randomized trial.
Fernando HC; Landreneau RJ; Mandrekar SJ; Nichols FC; DiPetrillo TA; Meyers BF; Heron DE; Hillman SL; Jones DR; Starnes SL; Tan AD; Daly BD; Putnam JB;
J Thorac Cardiovasc Surg; 2015 Mar; 149(3):718-25; discussion 725-6. PubMed ID: 25500100
[TBL] [Abstract][Full Text] [Related]
37. Validation of the Brazilian Portuguese version of the University of California San Diego Shortness of Breath Questionnaire in patients with interstitial lung disease.
Silva H; Mantoani LC; Zamboti CL; Aguiar WF; Ries AL; Gonçalves AFL; Silva TGD; Ribeiro M; Pitta F; Camillo CA
J Bras Pneumol; 2021; 47(6):e20210172. PubMed ID: 34932719
[TBL] [Abstract][Full Text] [Related]
38. Using a self-reported functional score to assess disease progression in systemic sclerosis.
Serednicka K; Smyth AE; Black CM; Denton CP
Rheumatology (Oxford); 2007 Jul; 46(7):1107-10. PubMed ID: 17426141
[TBL] [Abstract][Full Text] [Related]
39. Association of pruritus with quality of life and disability in systemic sclerosis.
El-Baalbaki G; Razykov I; Hudson M; Bassel M; Baron M; Thombs BD;
Arthritis Care Res (Hoboken); 2010 Oct; 62(10):1489-95. PubMed ID: 20506531
[TBL] [Abstract][Full Text] [Related]
40. Small, moderate, and large changes, and the minimum clinically important difference in the University of California, San Diego Shortness of Breath Questionnaire.
Horita N; Miyazawa N; Morita S; Kojima R; Kimura N; Kaneko T; Ishigatsubo Y
COPD; 2014 Feb; 11(1):26-32. PubMed ID: 23886071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
